XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
32.06
+1.17 (3.79%)
Aug 14, 2025, 11:48 AM - Market open
XOMA Royalty Revenue
XOMA Royalty had revenue of $13.13M in the quarter ending June 30, 2025, with 18.43% growth. This brings the company's revenue in the last twelve months to $44.95M, up 194.98% year-over-year. In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth.
Revenue (ttm)
$44.95M
Revenue Growth
+194.98%
P/S Ratio
8.17
Revenue / Employee
$3,457,846
Employees
13
Market Cap
383.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
XOMA News
- 1 day ago - XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewsWire
- 8 days ago - HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX - Business Wire
- 8 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc. - PRNewsWire
- 10 days ago - XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right - GlobeNewsWire
- 4 weeks ago - ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction - PRNewsWire
- 5 weeks ago - Collect Up To 11.5% From The Healthcare Sector - Seeking Alpha
- 6 weeks ago - Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right - GlobeNewsWire
- 2 months ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire